To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD)
Clinical trial NCT04770935 · COMPLETED
Trial details
- NCT number
- NCT04770935
- Sponsor
- Bioverativ, a Sanofi company
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-03
- Primary completion
- 2022-12-01
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.